Polymorphisms in the human AH receptor

Chemico-Biological Interactions

Volumn 141, Issue 1-2, 2002, Pages 161-187

  Harper, Patricia A ^a,b   Wong, Judy M Y ^b   Lam, Maria S M ^b   Okey, Allan B ^b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

2,3,7,8 Tetrachlorodibenzo p dioxin; AH receptor; Dioxin; Polymorphism; TCDD

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; NUCLEOTIDE; XENOBIOTIC AGENT;

ARTICLE; CELL CULTURE; CODON; ETHNIC DIFFERENCE; FUNCTION TEST; GENE CONSTRUCT; GENE FREQUENCY; GENE SEQUENCE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; GUINEA PIG; HAMSTER; HEALTH CARE; HUMAN; IN VITRO STUDY; LYMPHOCYTE; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; POPULATION RESEARCH; PROTEIN FUNCTION;

ANIMALS; CONTINENTAL POPULATION GROUPS; HUMANS; LINKAGE DISEQUILIBRIUM; MODELS, ANIMAL; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, ARYL HYDROCARBON; XENOBIOTICS;

ANIMALIA; MAMMALIA;

EID: 0037145057     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(02)00071-6     Document Type: Article

References (120)

1. Nebert D.W., Ingelman-Sundberg M., Daly A.K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab. Rev. 31:1999;467-487.
2. Park B.K., Kitteringham N.R., Powell H., Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology. 153:2000;39-60.
3. Kalow W. Interethnic differences in drug responses. Kalow W., Meyer U.A., Tyndale R.F., Pharmacogenomics. 2001;109-135 Marcel Dekker, Inc, New York, Basel.
4. Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab. Dispos. 29:2001;570-573.
5. Lin J.H., Lu A.Y. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 41:2001;535-567.
6. Miller M.P., Kumar S. Understanding human disease mutations through the use of interspecific genetic variation. Hum. Mol. Genet. 10:2001;2319-2328.
7. Xie H.G., Kim R.B., Wood A.J., Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41:2001;815-850.
8. Okey A.B., Riddick D.S., Harper P.A. Molecular biology of the aromatic hydrocarbon (dioxin) receptor. Trends Pharmacol. Sci. 15:1994;226-232.
9. Hahn M.E. The aryl hydrocarbon receptor: a comparative perspective. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 121:1998;23-53.
10. Matikainen T., Perez G.I., Jurisicova A., Pru J.K., Schlezinger J.J., Ryu H.Y., Laine J., Sakai T., Korsmeyer S.J., Casper R.F., Sherr D.H., Tilly J.L. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat. Genet. 28:2001;355-360.
11. Safe S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol. Lett. 120:2001;1-7.
12. Pohjanvirta R., Tuomisto J. Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals: effect, mechanisms, and animal models. Pharmacol. Rev. 46:1994;483-549.
13. Poland A., Glover E., Kende A.S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 251:1976;4936-4946.
14. Nebert D.W. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 20:1989;153-174.
15. b-3 alleles. Mol. Pharmacol. 38:1990;306-312.
16. Okey A.B., Vella L.M., Harper P.A. Detection and characterization of a 'low-affinity' form of Ah receptor in livers of mice 'nonresponsive' to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol. Pharmacol. 35:1989;823-830.
17. Poland A., Knutson J.C. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu. Rev. Pharmacol. Toxicol. 22:1982;517-554.
18. Ema M., Ohe N., Suzuki M., Mimura J., Sogawa K., Ikawa S., Fujii-Kuriyama Y. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J. Biol. Chem. 269:1994;27 337-27 343.
19. Poland A., Palen D., Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol. Pharmacol. 46:1994;915-921.
20. Schmidt J.V., Carver L.A., Bradfield C.A. Molecular characterization of the murine Ahr gene. Organization, promoter analysis, and chromosomal assignment. J. Biol. Chem. 268:1993;22 203-22 209.
21. Thomas R.S., Penn S.G., Holden K., Bradfield C.A., Rank D.R. Sequence variation and phylogenetic history of the mouse Ahr gene. Pharmacogenetics. 12:2002;151-163.
22. Fujii-Kuriyama Y., Ema M., Mimura J., Matsushita N., Sogawa K. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics. 5:1995;S149-S153.
23. Fernandez-Salguero P., Pineau T., Hilbert D.M., McPhail T., Lee S.S.T., Kimura S., Nebert D., Rudikoff S., Ward J.M., Gonzalez F.J. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science. 268:1995;722-726.
24. Schmidt J.V., Su G.H., Reddy J.K., Simon M.C., Bradfield C.A. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc. Natl. Acad. Sci. USA. 93:1996;6731-6736.
25. Fernandez-Salguero P.M., Hilbert D.M., Rudikoff S., Ward J.M., Gonzalez F.J. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol. 140:1996;173-179.
26. Thurmond T.S., Silverstone A.E., Baggs R.B., Quimby F.W., Staples J.E., Gasiewicz T.A. A chimeric aryl hydrocarbon receptor knockout mouse model indicates that aryl hydrocarbon receptor activation in hematopoietic cells contributes to the hepatic lesions induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 158:1999;33-40.
27. Mimura J., Yamashita K., Nakamura K., Morita M., Takagi T.N., Nakao K., Ema M., Sogawa K., Yasuda M., Katsuki M., Fujii-Kuriyama Y. Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells. 2:1997;645-654.
28. Lin T.M., Ko K., Moore R.W., Buchanan D.L., Cooke P.S., Peterson R.E. Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed male mice. J. Toxicol. Environ. Health A. 64:2001;327-342.
29. Shimizu Y., Nakatsuru Y., Ichinose M., Takahashi Y., Kume H., Mimura J., Fujii-Kuriyama Y., Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. USA. 97:2000;779-782.
30. Lahvis G.P., Lindell S.L., Thomas R.S., McCuskey R.S., Murphy C., Glover E., Bentz M., Southard J., Bradfield C.A. Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 97:2000;10 442-10 447.
31. Pohjanvirta R., Wong J.M., Li W., Harper P.A., Tuomisto J., Okey A.B. Point mutation in intron sequence causes altered carboxyl-terminal structure in the aryl hydrocarbon receptor of the most 2,3,7,8-tetrachlorodibenzo-p-dioxin-resistant rat strain. Mol. Pharmacol. 54:1998;86-93.
32. Tuomisto J.T., Viluksela M., Pohjanvirta R., Tuomisto J. The AH receptor and a novel gene determine acute toxic responses to TCDD: segregation of the resistant alleles to different rat lines. Toxicol. Appl. Pharmacol. 155:1999;71-81.
33. Jain S., Dolwick K.M., Schmidt J.V., Bradfield C.A. Potent transactivation domains of the Ah receptor and the Ah receptor nuclear translocator map to their carboxyl termini. J. Biol. Chem. 269:1994;31 518-31 524.
34. Ma Q., Dong L., Whitlock J.P. Jr. Transcriptional activation by the mouse Ah receptor. Interplay between multiple stimulatory and inhibitory functions. J. Biol. Chem. 270:1995;12 697-12 703.
35. Whitelaw M.L., Gustafsson J.A., Poellinger L. Identification of transactivation and repression functions of the dioxin receptor and its basic helix-loop-helix/PAS partner factor Arnt: inducible versus constitutive modes of regulation. Mol. Cell. Biol. 14:1994;8343-8355.
36. Bank P., Yao E.F., Phelps C.L., Harper P.A., Denison M.S. Species-specific binding of transformed Ah receptor to a dioxin responsive transcriptional enhancer. Eur. J. Pharm. 228:1992;85-94.
37. Swanson H.I., Tullis K., Denison M.S. Binding of transformed Ah receptor complex to a dioxin responsive transcriptional enhancer: evidence for two distinct heteromeric DNA-binding forms. Biochemistry. 32:1993;12 841-12 849.
38. Bank P.A., Yao E.F., Swanson H.I., Tullis K., Denison M.S. DNA binding of the transformed guinea pig hepatic Ah receptor complex: identification and partial characterization of two high-affinity DNA-binding forms. Arch. Biochem. Biophys. 317:1995;439-448.
39. Korkalainen M., Tuomisto J., Pohjanvirta R. Restructured transactivation domain in hamster AH receptor. Biochem. Biophys. Res. Commun. 273:2000;272-281.
40. Korkalainen M., Tuomisto J., Pohjanvirta R. The AH receptor of the most dioxin-sensitive species, guinea pig, is highly homologous to the human AH receptor. Biochem. Biophys. Res. Commun. 285:2001;1121-1129.
41. Micka J., Milatovich A., Menon A., Grabowski G.A., Puga A., Nebert D.W. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics. 7:1997;95-101.
42. Harper P.A., Prokipcak R.D., Bush L.E., Golas C.L., Okey A.B. Detection and characterization of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in the human colon adenocarcinoma cell line LS180. Arch. Biochem. Biophys. 290:1991;27-36.
43. Kawajiri K., Watanabe J., Eguchi H., Nakachi K., Kiyohara C., Hayashi S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics. 5:1995;151-158.
44. Smart J., Daly A.K. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics. 10:2000;11-24.
45. Wong J.M.Y., Okey A.B., Harper P.A. Human aryl hydrocarbon receptor polymorphisms that result in loss of CYP1A1 induction. Biochem. Biophys. Res. Commun. 288:2001;990-996.
46. Cauchi S., Stucker I., Solas C., Laurent-Puig P., Cenee S., Hemon D., Jacquet M., Kremers P., Beaune P., Massaad-Massade L. Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis. 22:2001;1819-1824.
47. Anttila S., Lei X.D., Elovaara E., Karjalainen A., Sun W., Vainio H., Hankinson O. An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics. 10:2000;741-751.
48. M.S.M. Lam, H. Jernstrom, P.A. Harper, A.B. Okey, J.M.Y. Wong, B.K. Tang, H.L. Bradlow, D.W. Sepkovic, D. Vesprini, S.S. Narod, Genetic polymorphisms in human AH receptor and cytochrome P450 enzymes in relation to in vivo estradiol metabolism, Cancer Epidemiol. Biomarkers Prev. submitted (2002).
49. Zhang D.S., Lin G.F., Ma Q.W., Shen J.H. Nonassociation of aryl hydrocarbon receptor genotypes with susceptibility to bladder cancer in Shanghai population. Acta Pharmacol. Sin. 23:2002;188-192.
50. Gu Y.-Z., Hogenesch J.B., Bradfield C.A. The PAS superfamily: sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 40:2000;519-561.
51. Hahn M.E., Karchner S.I., Shapiro M.A., Perera S.A. Molecular evolution of two vertebrate aryl hydrocarbon (dioxin) receptors (AHR1 and AHR2) and the PAS family. Proc. Natl. Acad. Sci. USA. 94:1997;13 743-13 748.
52. Karchner S.I., Franks D.G., Powell W.H., Hahn M.E. Regulatory interactions among three members of the vertebrate aryl hydrocarbon receptor family: AHR repressor, AHR1, and AHR2. J. Biol. Chem. 277:2002;6949-6959.
53. Mimura J., Ema M., Sogawa K., Fujii-Kuriyama Y. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev. 13:1999;20-25.
54. Watanabe T., Imoto I., Kosugi Y., Fukuda Y., Mimura J., Fujii Y., Isaka K., Takayama M., Sato A., Inazawa J. Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis. J. Hum. Genet. 46:2001;342-346.
55. Baba T., Mimura J., Gradin K., Kuroiwa A., Watanabe T., Matsuda Y., Inazawa J., Sogawa K., Fujii-Kuriyama Y. Structure and expression of the Ah receptor repressor gene. J. Biol. Chem. 276:2001;33 101-33 110.
56. Fujita H., Kosaki R., Yoshihashi H., Ogata T., Tomita M., Hasegawa T., Takahashi T., Matsuo N., Kosaki K. Characterization of the aryl hydrocarbon receptor repressor gene and association of its Pro185Ala polymorphism with micropenis. Teratology. 65:2002;10-18.
57. Antonarakis S.E. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum. Mutat. 11:1998;1-3.
58. den Dunnen J.T., Antonarakis S.E. Nomenclature for the description of human sequence variations. Hum. Genet. 109:2001;121-124.
59. Eguchi H., Hayashi S., Watanabe J., Gotoh O., Kawajiri K. Molecular cloning of the human AH receptor gene promoter. Biochem. Biophys. Res. Commun. 203:1994;615-622.
60. Takahashi Y., Itoh S., Shimojima T., Kamataki T. Characterization of Ah receptor promoter in human liver cell line, HepG2. Pharmacogenetics. 4:1994;219-222.
61. Ingelman-Sundberg M., Oscarson M., Daly A.K., Garte S., Nebert D.W. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol. Biomarkers Prev. 10:2001;1307-1308.
62. Okey A.B., Riddick D.S., Harper P.A. The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Lett. 70:1994;1-22.
63. Nebert D.W., Roe A.L., Dieter M.Z., Solis W.A., Yang Y., Dalton T.P. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 59:2000;65-85.
64. Kellermann G., Cantrell E., Shaw C.R. Variations in extent of aryl hydrocarbon hydroxylase induction in cultured human lymphocytes. Cancer Res. 33:1973;1654-1656.
65. Nebert D.W., Jensen N.M. The Ah locus: genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases. CRC Crit. Rev. Biochem. 6:1979;401-437.
66. Kouri R.E., McKinney C.E., Slomiany D.J., Snodgrass D.R., Wray N.P., McLemore T.L. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 42:1982;5030-5037.
67. Catteau A., Douriez E., Beaune P., Poisson N., Bonaiti-Pellie C., Laurent P. Genetic polymorphism of induction of CYP1A1 (EROD) activity. Pharmacogenetics. 5:1995;110-119.
68. Smith G.B., Harper P.A., Wong J.M., Lam M.S., Reid K.R., Petsikas D., Massey T.E. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol. Biomarkers Prev. 10:2001;839-853.
69. Kalow W., Tang B.K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther. 50:1991;508-519.
70. Tang B.K., Kalow W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol. 272:1996;124-131.
71. Lu L.J., Anderson K.E., Grady J.J., Kohen F., Nagamani M. Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res. 60:2000;4112-4121.
72. Murray S., Lake B.G., Gray S., Edwards A.J., Springall C., Bowey E.A., Williamson G., Boobis A.R., Gooderham N.J. Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. Carcinogenesis. 22:2001;1413-1420.
73. Jellinck P.H., Forkert P.G., Riddick D.S., Okey A.B., Michnovicz J.J., Bradlow H.L. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem. Pharmacol. 45:1993;1129-1136.
74. Chen Y.H., Riby J., Srivastava P., Bartholomew J., Denison M., Bjeldanes L. Regulation of CYP1A1 by indolo[3,2-b]carbazole in murine hepatoma cells. J. Biol. Chem. 270:1995;22 548-22 555.
75. Stephensen P.U., Bonnesen C., Schaldach C., Andersen O., Bjeldanes L.F., Vang O. N-methoxyindole-3-carbinol is a more efficient inducer of cytochrome P-450 1A1 in cultured cells than indol-3-carbinol. Nutr. Cancer. 36:2000;112-121.
76. Michnovicz J.J., Adlercreutz H., Bradlow H.L. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J. Natl. Cancer Inst. 89:1997;718-723.
77. Bell M.C., Crowley-Nowick P., Bradlow H.L., Sepkovic D.W., Schmidt-Grimminger D., Howell P., Mayeaux E.J., Tucker A., Turbat-Herrera E.A., Mathis J.M. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol. 78:2000;123-129.
78. Wong J.M., Harper P.A., Meyer U.A., Bock K.W., Morike K., Lagueux J., Ayotte P., Tyndale R.F., Sellers E.M., Manchester D.K., Okey A.B. Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics. 11:2001;85-94.
79. Maier A., Micka J., Miller K., Denko T., Chang C.Y., Nebert D.W., Puga A. Aromatic hydrocarbon receptor polymorphism: development of new methods to correlate genotype with phenotype. Environ. Health Perspect. 106:1998;421-426.
80. Carver L.A., Jackiw V., Bradfield C.A. The 90-kDa heat shock protein is essential for AH receptor signaling in a yeast expression system. J. Biol. Chem. 269:1994;301 109-330 112.
81. Rowlands J.C., Gustafsson J.A. Human dioxin receptor chimera transactivation in a yeast model system and studies on receptor agonists and antagonists. Pharmacol. Toxicol. 76:1995;328-333.
82. Dzeletovic N., McGuire J., Daujat M., Tholander J., Ema M., Fujii-Kuriyama Y., Bergman J., Maurel P., Poellinger L. Regulation of dioxin receptor function by omeprazole. J. Biol. Chem. 272:1997;12 705-12 713.
83. Ivy S.P., Tulpule A., Fairchild C.R., Averbuch S.D., Myers C.E., Nebert D.W., Baird W.M., Cowan K.H. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J. Biol. Chem. 263:1988;19 119-19 125.
84. Chang K.-W., Lee H., Wang H.-J., Chen S.-Y., Lin P. Differential response to benzo[a]pyrene in human lung adenocarcinoma cell lines: the absence of aryl hydrocarbon receptor activation. Life Sci. 65:1999;1339-1349.
85. Roberts E.A., Harper P.A., Wong J.M., Wang Y., Yang S. Failure of Ah receptor to mediate induction of cytochromes P450 in the CYP1 family in the human hepatoma line SK-Hep-1. Arch. Biochem. Biophys. 384:2000;190-198.
86. Anttila S., Tuominen P., Hirvonen A., Nurminen M., Karjalainen A., Hankinson O., Elovaara E. CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics. 11:2001;501-509.
87. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J. Clin. Psychopharmacol. 21:2001;398-407.
88. Hayashi S., Watanabe J., Nakachi K., Eguchi H., Gotoh O., Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis. 15:1994;801-806.
89. Cao H., Hegele R.A. Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. J. Hum. Genet. 45:2000;92-93.
90. Kumar M.B., Ramadoss P., Reen R.K., Vanden Heuvel J.P., Perdew G.H. The Q-rich sub-domain of the human Ah receptor transactivation domain is required for dioxin-mediated transcriptional activity. J. Biol. Chem. 276:2001;42 302-42 310.
91. Eguchi H., Ikuta T., Tachibana T., Yoneda Y., Kawajiri K. A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor 1β is a novel bipartite type recognized by the two components of nuclear pore-targeting complex. J. Biol. Chem. 272:1997;17 640-17 647.
92. Ikuta T., Eguchi H., Tachibana T., Yoneda Y., Kawajiri K. Nuclear localization and export signals of the human aryl hydrocarbon receptor. J. Biol. Chem. 273:1998;2895-2904.
93. Kazlauskas A., Sundstrom S., Poellinger L., Pongratz I. The hsp90 chaperone complex regulates intracellular localization of the dioxin receptor. Mol. Cell. Biol. 21:2001;2594-2607.
94. Kumar M.B., Perdew G.H. Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. Gene Expr. 8:1999;273-286.
95. Roberts B.J., Whitelaw M.L. Degradation of the basic helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor via the ubiquitin/proteasome pathway. J. Biol. Chem. 274:1999;36 351-36 356.
96. Ma Q., Renzelli A.J., Baldwin K.T., Antonini J.M. Superinduction of CYP1A1 gene expression. Regulation of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of Ah receptor by cycloheximide. J. Biol. Chem. 275:2000;12 676-12 683.
97. Ma Q., Baldwin K.T. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the ubiquitin-proteasome pathway. Role of the transcription activation and DNA binding of AhR. J. Biol. Chem. 275:2000;8432-8438.
98. Sunyaev S., Hanke J., Brett D., Aydin A., Zastrow I., Lathe W., Bork P., Reich J. Individual variation in protein-coding sequences of human genome. Adv. Protein Chem. 54:2000;409-437.
99. Hirschhorn J.N., Lohmueller K., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Genet. Med. 4:2002;45-61.
100. Trikka D., Fang Z., Renwick A., Jones S.H., Chakraborty R., Kimmel M., Nelson D.L. Complex SNP-based haplotypes in three human helicases: implications for cancer association studies. Genome Res. 12:2002;627-639.
101. Fredman D., Siegfried M., Yuan Y.P., Bork P., Lehvaslaiho H., Brookes A.J. HGVbase: a human sequence variation database emphasizing data quality and a broad spectrum of data sources. Nucl. Acids Res. 30:2002;387-391.
102. Kalow W. Pharmacoanthropology and the genetics of drug metabolism. Kalow W., Pharmacogenetics of Drug Metabolism. 1992;865-877 Pergamon Press, New York.
103. Jones L.C., Whitlock J.P. Jr. Dioxin-inducible transactivation in a chromosomal setting. Analysis of the acidic domain of the Ah receptor. J. Biol. Chem. 276:2001;25 037-25 042.
104. Guo Y.L., Yu M.L., Hsu C.C., Rogan W.J. Chloracne, goiter, arthritis, and anemia after polychlorinated biphenyl poisoning: 14-year follow-up of the Taiwan Yucheng cohort. Environ. Health Perspect. 107:1999;715-719.
105. Geusau A., Abraham K., Geissler K., Sator M.O., Stingl G., Tschachler E. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects. Environ. Health Perspect. 109:2001;865-869.
106. Bertazzi P.A., Bernucci I., Brambilla G., Consonni D., Pesatori A.C. The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ. Health Perspect. 106:(Suppl. 2):1998;625-633.
107. Wanner R., Zober A., Abrham K., Kleffe J., Henz B.M., Wittig B. Polymorphisms at codon 554 of the human Ah receptor: different allelic frequencies in Caucasians and Japanese and no correlation with severity of TCDD induced chloracne in chemical workers. Pharmacogenetics. 9:1999;777-780.
108. Eskenazi B., Mocarelli P., Warner M., Samuels S., Vercellini P., Olive D., Needham L., Patterson D., Brambilla P. Seveso Women's Health Study: a study of the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on reproductive health. Chemosphere. 40:2000;1247-1253.
109. Harper P.A., Golas C.L., Okey A.B. Characterization of the Ah receptor and aryl hydrocarbon hydroxylase induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and benz(a)anthracene in the human A431 squamous cell carcinoma line. Cancer Res. 48:1988;2388-2395.
110. Li W., Harper P.A., Tang B.K., Okey A.B. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem. Pharmacol. 56:1998;599-612.
111. Zeiger M., Haag R., Hockel J., Schrenk D., Schmitz H.J. Inducing effects of dioxin-like polychlorinated biphenyls on CYP1A in the human hepatoblastoma cell line HepG2, the rat hepatoma cell line H4IIE, and rat primary hepatocytes: comparison of relative potencies. Toxicol. Sci. 63:2001;65-73.
112. Itoh S., Kamataki T. Human Ah receptor cDNA: analysis for highly conserved sequences. Nucl. Acids Res. 21:1993;3578.
113. Rivera S.P., Saarikoski S.T., Hankinson O. Identification of a novel dioxin-inducible cytochrome P450. Mol. Pharmacol. 61:2002;255-259.
114. Frueh F.W., Hayashibara K.C., Brown P.O., Whitlock J.P. Jr. Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression. Toxicol. Lett. 122:2001;189-203.
115. Puga A., Maier A., Medvedovic M. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem. Pharmacol. 60:2000;1129-1142.
116. Gao L., Dong L., Whitlock J.P. Jr. A novel response to dioxin. Induction of ecto-ATPase gene expression. J. Biol. Chem. 273:1998;15 358-15 365.
117. Kolluri S.K., Weiss C., Koff A., Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev. 13:1999;1742-1753.
118. Kolluri S.K., Balduf C., Hofmann M., Gottlicher M. Novel target genes of the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Res. 61:2001;8534-8539.
119. Yang D., Li Y., Yuan X., Matoney L., Yan B. Regulation of rat carboxylesterase expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): a dose-dependent decrease in mRNA levels but a biphasic change in protein levels and activity. Toxicol. Sci. 64:2001;20-27.
120. Manchester D.K., Gordon S.K., Golas C.L., Roberts E.A., Okey A.B. Ah receptor in human placenta: stabilization by molybdate and characterization of binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methylcholanthrene, and benzo[a]pyrene. Cancer Res. 47:1987;4861-4868.